31.9 C
Vientiane
Wednesday, August 6, 2025
spot_img
Home Blog Page 118

Seegene unveils the world’s first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

  • Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts in Chicago, July 28–31
  • Unifying global diagnostic data – STAgora™, the big data platform set to transform the future of diagnostics
  • Pilot partnerships to offer early access to the new diagnostic paradigm, with selected institutions engaged by year-end

SEOUL, South Korea, July 23, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world’s largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm.

Seegene will present a live demonstration of CURECA™ (pictured), its next-generation fully automated PCR testing system in ADLM 2025, held in Chicago from July 28 to 31. CURECA™ integrates three core modules: a prep module for pre-analytical processing, a diagnostic module for assay execution, and a software module for data analysis.
Seegene will present a live demonstration of CURECA™ (pictured), its next-generation fully automated PCR testing system in ADLM 2025, held in Chicago from July 28 to 31. CURECA™ integrates three core modules: a prep module for pre-analytical processing, a diagnostic module for assay execution, and a software module for data analysis.

Automating every step of PCR Testing for enhanced efficiency and accuracy

CURECA™ is the world’s first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results.

A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling.

The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments.

In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory.

STAogra – Real-Time Global Data Integration Empowering Personalized Care

Also unveiled at ADLM 2025, STAgora™ is Seegene’s statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support.

With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making.

Expanding Global Collaboration via Technology Sharing and Strategic Partnerships

Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships.

Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe’s leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

“CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we’ve built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem.” Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene.

Disclaimer

The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales.

About Seegene

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc

AVer Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Medical-Grade PTZ Cameras

Recognized for its AI-driven innovation, platform-agnostic product design, and exceptional customer-centric healthcare video solutions

SAN ANTONIO, July 23, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that AVer Information Inc. has received the 2025 Global Company of the Year Recognition in the medical-grade PTZ cameras industry for its outstanding achievements in technology innovation, healthcare-focused strategy execution, and customer impact. This recognition highlights AVer’s consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation in an evolving competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. AVer excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. “AVer is right in the middle of a significant transformation in healthcare delivery, with products and services that enable and positively contribute to this change,” said David Frigstad, Chairman at Frost & Sullivan.

Guided by a long-term growth strategy focused on AI-driven innovation, platform-agnostic product design, and healthcare collaboration, AVer has shown its ability to adapt and lead in a rapidly evolving landscape. The company’s strategic agility and sustained investment in connected healthcare solutions have enabled it to scale effectively across clinical and homecare environments.

Innovation remains central to AVer’s approach. Its suite of medical-grade PTZ cameras addresses the full spectrum of telehealth, tele-ICU, tele-sitting, and remote patient monitoring needs, offering seamless integration, scalability, and high-performance video capabilities. “We are thrilled to receive this prestigious award from Frost & Sullivan, one of the leading research firms in the healthcare industry,” said Andy Hsi, CEO, AVer Information Inc. “AVer as a company is committed to making a positive difference in the revolutionary telehealth industry, empower smart healthcare environments and help create better patient outcomes for caregivers with our AI and video innovations.”

AVer’s unwavering commitment to customer experience further strengthens its position in the market. By offering robust support resources—such as training videos, comprehensive manuals, and localized expert assistance via phone, email, or video conferencing—the company ensures that every implementation is successful. Its platform-agnostic camera designs simplify deployments across diverse healthcare settings, enhancing adoption and long-term value.

Frost & Sullivan commends AVer for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of connected healthcare and driving tangible results at scale.

Each year, Frost & Sullivan presents the Company of the Year Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Camila Tinajero
E: camila.tinajero@frost.com  

About AVer Information Inc.

Founded in 2008, AVer is an award-winning provider of education technology, healthcare and video collaboration camera solutions that improve productivity and enrich learning. From accelerating learning in the classroom, safely supporting patient care, to increasing competitive advantage for businesses, AVer solutions leverage the power of technology to help people connect with one another to achieve great things. Our product portfolio includes Professional Grade Artificial Intelligence Enabled Auto Tracking Cameras, Medical Grade PTZ Cameras, Zoom and Microsoft Teams Certified Enterprise Grade USB Cameras, Document Cameras and Classroom Audio Solutions. We strive to provide industry leading service and support that exceeds our customer’s expectations. We are also deeply committed to our community, the environment and employ stringent green processes in all we do.

NovaSource Power Services Named O&M Partner for Landmark Melbourne Renewable Energy Hub in Australia

CHANDLER, Ariz., July 23, 2025 /PRNewswire/ — NovaSource Power Services (“NovaSource”), the world’s largest solar operations and maintenance (“O&M”) provider, has been selected by Equis as the long-term O&M partner for the Melbourne Renewable Energy Hub (“MREH”), a groundbreaking project set to become one of Australia’s largest batteries and a key driver of the nation’s clean energy transition.


MREH is uniquely positioned at the intersection of Victoria’s critical transmission corridors and capable of supporting three major Renewable Energy Zones: Murray River, Western Victoria, and South Victoria. Developed in partnership between the Victorian government owned SEC, and Equis, when it comes online in late 2025, the project will provide 600 megawatts of capacity and 1.6 gigawatt hours of storage.

Upon completion, MREH will rank among the world’s largest batteries with its 1.6 GWh total capacity. More than just an infrastructure project, MREH represents a key investment in Victoria’s clean energy future, directly supporting the state’s 2035 target of 95% renewable energy generation while setting new benchmarks for large-scale energy storage technology. 

“Being chosen by Equis to support this transformative project reflects NovaSource’s global leadership in asset optimization and utility-scale O&M,” said Irfan Bharde, SVP & Chief Commercial Officer at NovaSource Power Services.

Ayssar Alsayed, NovaSource’s Country Manager in Australia, added, “We’re proud to bring our expertise in performance engineering, predictive analytics, and system maintenance to ensure the MREH delivers lasting value for Australia’s energy future.”

Under the agreement, NovaSource will provide comprehensive O&M services, including 24/7/365 performance monitoring, predictive maintenance, and specialized support for energy systems. These solutions will maximize system uptime, energy yield, and long-term asset performance for the MREH.

This partnership further expands NovaSource’s growing footprint in APAC, reinforcing its role in advancing the region’s renewable energy landscape. By combining cutting-edge digital solutions with deep industry expertise and field services, NovaSource continues to lead the charge in optimizing renewable assets and powering the global energy transition.

About NovaSource Power Services

NovaSource Power Services (“NovaSource”), a portfolio company of Clairvest Group Inc. (“Clairvest”, TSX: CVG) and OMERS Private Equity, the private equity arm of OMERS, is the world’s largest independent solar operations and maintenance (“O&M”) provider, delivering excellence through data-driven strategies, innovative solutions, and a world-class culture of safety, integrity, and quality.

NovaSource’s comprehensive approach to total asset optimization in addition to operations and maintenance includes value engineering, performance analysis, strategic supply chain management, and advanced monitoring systems. The company operates in key global markets and across most U.S. states managing over 30GW of solar power plants. NovaSource’s expertise extends beyond solar and includes battery energy storage systems (BESS), offering a complete suite of services for the evolving renewable energy landscape. For more information about NovaSource Power Services, please visit www.novasourcepower.com or follow @NovaSourcePower on LinkedIn

Photo – https://laotiantimes.com/wp-content/uploads/2025/07/novasource_mreh_au.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/07/novasource_logo.jpg

Madame Tussauds Unveils 13 New Taylor Swift Figures in Historic Global Launch

Madame Tussauds Hong Kong’s new Taylor Swift wax figure will celebrate the folklore era, as part of the global entertainment brand’s biggest launch to date


HONG KONG SAR – Media OutReach Newswire – 23 July 2025 – In news that’s sure to make every Swiftie’s wildest dreams come true, global entertainment brand Madame Tussauds today unveils its biggest figure launch to date, creating not one, but 13 brand new Taylor Swift wax figures. The figures, launching in 13 cities across four continents, will make guests feel as if they’ve stepped on stage at Taylor Swift | The Eras Tour.

@madametussaudshongkong #madametussaudshongkong #ThePeak

This simultaneous multi-figure launch is the most ambitious in Madame Tussauds’ 250-year history, reflecting Taylor Swift’s standing as one of the most influential and enduring artists of the 21st century. The trailblazing star recently wrapped her record-breaking Taylor Swift | The Eras Tour – selling-out 149 dates across five continents – and now Madame Tussauds marks this legacy by immortalising iconic moments from the historic tour for fans around the world.

Laura Sheard, Global Brand Director at Madame Tussauds, said: “Taylor Swift is a generational icon and a cultural powerhouse. Madame Tussauds has a centuries-old legacy of holding a mirror up to the world of fame, immortalising the profiles that are making an imprint on the day’s culture. Taylor Swift’s influence spans music, fashion, film, activism and even the economy. The phenomenal success of her record-smashing tour is the perfect moment for Madame Tussauds to immortalise with 13 figures – Taylor’s lucky number – across four continents to ensure we’re reaching as many fans as possible. We just know they are going to love it as much as we do.”

A team of more than 40 highly skilled Madame Tussauds artists has been working tirelessly for 14 months on the exciting project, which features each of the 13 figures dressed in a unique fan-favourite look from Taylor Swift | The Eras Tour. Images and footage released today reveal the Madame Tussauds Hong Kong figure celebrates the folklore era in show-stopping style.

Featuring dramatic split sleeves and leaf detailing embellishment, the new figure is dressed in a flowing green Alberta Ferretti dress, specially created by the designer for Madame Tussauds Hong Kong. The look is finished with green lace up boots and bespoke microphone created by Rebel Stage Gear UK, the specialist customisation company behind the original microphones Taylor used during Taylor Swift | The Eras Tour.

Danielle Cullen, Madame Tussauds’ Senior Figure Stylist said:This is the most ambitious project in Madame Tussauds’ 250-year history which only feels right to reflect the stratospheric status of Taylor Swift. We’re honoured to have worked closely with fashion houses like Roberto Cavalli, Vivienne Westwood, Versace, Christian Louboutin, Alberta Ferretti and Etro to recreate some of the Taylor Swift | The Eras Tour’s most iconic looks – many of which will have special significance to the cities the 13 new figures will call home. It feels a fitting celebration to give Swifties the chance to commemorate moments from this once-in-a-generation tour in a way that only Madame Tussauds can.”

Today’s launch marks the biggest undertaking by Madame Tussauds since unveiling seven Harry Styles figures in 2023 and eight Lady Gaga figures in 2011. Rolling out across the world-famous entertainment brand’s global estate, the new figures will appear in the Amsterdam, Berlin, Blackpool, Budapest, Hollywood, Hong Kong, Las Vegas, London, Nashville, New York, Orlando and Sydney attractions, with a touring figure kicking off its residency in Shanghai.

Following today’s iconic unveiling, fans will be able to visit Madame Tussauds Hong Kong’s new Taylor Swift wax figure at the attraction from 24 July 2025. Keep an eye out on Madame Tussauds’ social channels for more news on this historic launch.

Madame Tussauds Hong Kong Social Media Accounts
Facebook: https://www.facebook.com/madametussaudshongkong/
Instagram: https://www.instagram.com/madametussaudshongkong/
YouTube: https://www.youtube.com/@TussaudsHK
Twitter: https://x.com/TussaudsHK
Xiaohongshu: https://shorturl.at/lVGJx
Douyin: https://shorturl.at/yIGF1
Weibo: https://weibo.com/mthk
WeChat: (Search “香港杜莎夫人蜡像馆”)

Hashtag: #madametussaudshongkong #ThePeak

The issuer is solely responsible for the content of this announcement.

About Madame Tussauds

Madame Tussauds has been inviting people to walk the red carpet and get closer to the revered for over 250 years. With 22 attractions in the world’s top destination cities, we are dedicated to giving millions of visitors the opportunity to mingle with the mighty from A-listers to music legends, heroes of sport, to world leaders. Today, we continue to partner with the global icons of a generation to create astonishing lifelike figures from sittings and offer exciting and interactive experiences to ensure guests have never felt closer to fame.

About Merlin Entertainments

Merlin Entertainments is a world leader in branded entertainment destinations, offering a diverse portfolio of resort theme parks, city-centre gateway attractions and LEGOLAND® Resorts which span across the UK, US, Western Europe, China and Asia Pacific. Dedicated to creating experiences that inspire joy and connection, Merlin welcomes more than 62 million guests annually to its diverse global estate in over 20 countries. An expert in bringing world-famous entertainment brands to life, Merlin works with partners including the LEGO® Group, Sony Pictures Entertainment, Peppa Pig, DreamWorks and Ferrari to create destinations where guests can immerse themselves in a wide array of brand-driven worlds, rides and uplifting learning experiences.

See for more information.

AVer Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Medical-Grade PTZ Cameras

Recognized for its AI-driven innovation, platform-agnostic product design, and exceptional customer-centric healthcare video solutions

SAN ANTONIO, July 23, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that AVer Information Inc. has received the 2025 Global Company of the Year Recognition in the medical-grade PTZ cameras industry for its outstanding achievements in technology innovation, healthcare-focused strategy execution, and customer impact. This recognition highlights AVer’s consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation in an evolving competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. AVer excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. “AVer is right in the middle of a significant transformation in healthcare delivery, with products and services that enable and positively contribute to this change,” said David Frigstad, Chairman at Frost & Sullivan.

Guided by a long-term growth strategy focused on AI-driven innovation, platform-agnostic product design, and healthcare collaboration, AVer has shown its ability to adapt and lead in a rapidly evolving landscape. The company’s strategic agility and sustained investment in connected healthcare solutions have enabled it to scale effectively across clinical and homecare environments.

Innovation remains central to AVer’s approach. Its suite of medical-grade PTZ cameras addresses the full spectrum of telehealth, tele-ICU, tele-sitting, and remote patient monitoring needs, offering seamless integration, scalability, and high-performance video capabilities. “We are thrilled to receive this prestigious award from Frost & Sullivan, one of the leading research firms in the healthcare industry,” said Andy Hsi, CEO, AVer Information Inc. “AVer as a company is committed to making a positive difference in the revolutionary telehealth industry, empower smart healthcare environments and help create better patient outcomes for caregivers with our AI and video innovations.”

AVer’s unwavering commitment to customer experience further strengthens its position in the market. By offering robust support resources—such as training videos, comprehensive manuals, and localized expert assistance via phone, email, or video conferencing—the company ensures that every implementation is successful. Its platform-agnostic camera designs simplify deployments across diverse healthcare settings, enhancing adoption and long-term value.

Frost & Sullivan commends AVer for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of connected healthcare and driving tangible results at scale.

Each year, Frost & Sullivan presents the Company of the Year Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Camila Tinajero
E: camila.tinajero@frost.com  

About AVer Information Inc.

Founded in 2008, AVer is an award-winning provider of education technology, healthcare and video collaboration camera solutions that improve productivity and enrich learning. From accelerating learning in the classroom, safely supporting patient care, to increasing competitive advantage for businesses, AVer solutions leverage the power of technology to help people connect with one another to achieve great things. Our product portfolio includes Professional Grade Artificial Intelligence Enabled Auto Tracking Cameras, Medical Grade PTZ Cameras, Zoom and Microsoft Teams Certified Enterprise Grade USB Cameras, Document Cameras and Classroom Audio Solutions. We strive to provide industry leading service and support that exceeds our customer’s expectations. We are also deeply committed to our community, the environment and employ stringent green processes in all we do.

Seegene unveils the world’s first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

  • Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts in Chicago, July 28–31
  • Unifying global diagnostic data – STAgora™, the big data platform set to transform the future of diagnostics
  • Pilot partnerships to offer early access to the new diagnostic paradigm, with selected institutions engaged by year-end

SEOUL, South Korea, July 23, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world’s largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm.

Seegene will present a live demonstration of CURECA™ (pictured), its next-generation fully automated PCR testing system in ADLM 2025, held in Chicago from July 28 to 31. CURECA™ integrates three core modules: a prep module for pre-analytical processing, a diagnostic module for assay execution, and a software module for data analysis.
Seegene will present a live demonstration of CURECA™ (pictured), its next-generation fully automated PCR testing system in ADLM 2025, held in Chicago from July 28 to 31. CURECA™ integrates three core modules: a prep module for pre-analytical processing, a diagnostic module for assay execution, and a software module for data analysis.

Automating every step of PCR Testing for enhanced efficiency and accuracy

CURECA™ is the world’s first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results.

A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling.

The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments.

In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory.

STAogra – Real-Time Global Data Integration Empowering Personalized Care

Also unveiled at ADLM 2025, STAgora™ is Seegene’s statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support.

With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making.

Expanding Global Collaboration via Technology Sharing and Strategic Partnerships

Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships.

Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe’s leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

“CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we’ve built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem.” Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene.

Disclaimer

The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales.

About Seegene

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

  • Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026
  • HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma
  • Extended dosing intervals could reduce treatment burden and improve outcomes for patients with advanced respiratory diseases 
  • Global COPD clinical program planned to start in mid-2026

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, July 23, 2025 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that its partner, Windward Bio AG (“Windward Bio”), has initiated the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. Initial data are expected in mid-2026.

Asthma is a chronic respiratory condition affecting approximately 300 million people worldwide, with prevalence continuing to rise. Despite the availability of treatment options, many patients experience persistent symptoms, frequent exacerbations, and reduced quality of life. Current therapies – mainly inhaled corticosteroids (ICS) and bronchodilators – are inadequate for some patients, underscoring the urgent need for more effective, long-acting treatments that address the underlying disease mechanisms.

HBM9378/WIN378 is a potentially best-in-class, long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological diseases, including asthma and chronic obstructive pulmonary disease (COPD). This molecule has fully human sequences, offering a lower risk of immunogenicity and improved bioavailability compared to other TSLP-targeting therapies. It has been engineered to achieve a half-life extension and a silenced effector function and is subcutaneously administered. In a Phase 1 trial, HBM9378/WIN378 demonstrated an extended half-life, showed a low incidence of antidrug antibodies, and was safe and well tolerated up to the highest tested dose.

“We are pleased to see HBM9378/WIN378 advancing rapidly into global clinical development,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “This long-acting, fully human anti-TSLP antibody has demonstrated strong potential in previous preclinical and clinical studies. We believe it has the potential to address significant unmet needs for patients with asthma.”

HBM9378/WIN378 (also known as SKB378) started as a co-development project jointly conducted by Harbour BioMed and Kelun-Biotech, with both parties equally sharing global rights. Earlier this year, Harbour BioMed and Kelun-Biotech entered into a strategic partnership with Windward Bio, granting Windward Bio an exclusive license to research, develop, manufacture, and commercialize this antibody globally, excluding Greater China and several Southeast and West Asian countries.

In addition to asthma, HBM9378/WIN378 is also being evaluated in clinical trials for COPD, another major respiratory condition. In November 2024, the Company submitted an Investigational New Drug (IND) application for HBM9378/WIN378 in COPD to the National Medical Products Administration (NMPA) of China, which was approved in January 2025. Additionally, Windward Bio plans to initiate global clinical trials in COPD in 2026. The continued progress of HBM9378/WIN378 in both asthma and COPD highlights the versatility and potential of this innovative therapy.

About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

About Windward Bio AG
Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specific antibodies targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

 

CeraVe Celebrates Two Decades of “Developed with Dermatologists” Skincare: A 20th Birthday Tribute to Skin Barrier Science and Innovations

A Global Celebration Unites Dermatologists, Influencers, and Innovators in New York City to Mark 20 Years of the Iconic Skincare Brand

NEW YORK, July 23, 2025 /PRNewswire/ — It’s CeraVe-time to celebrate! CeraVe, the global skincare brand recommended by 80,000 dermatologists worldwide1, is celebrating a major milestone: 20 years of skin barrier authority, championing barrier health and delivering effective, skin identical ceramide and MVE solutions to provide accessible, therapeutic skincare solutions for everybody everywhere.

Over the past two decades, CeraVe has catapulted from a local US derm-backed secret to a global phenomenon, building an inclusive brand that appeals to all genders and generations. What remains unchanged is the brand’s foundational insights: that most skin issues are linked to skin barrier disruption, and that skin identical ceramides are key to restoring and maintaining it. That insight began with three core products: Moisturizing Cream, Moisturizing Lotion and Hydrating Cleanser, and today powers a global portfolio of more than 90 barrier-supporting products. This unwavering dedication to its foundational insights, supported by its expertise as a skin barrier authority and its dermatologist-led development, has been the driving force behind CeraVe’s remarkable exponential expansion, leading to an impressive 10X growth since its inception, and crossing the $2 billion mark in global sales last year.

From the very beginning, CeraVe has revolutionized the skincare landscape as the first brand to be developed with dermatologists – not as a slogan, but as a guiding philosophy and scientific foundation. Every formula, every innovation, every product begins and ends with the expertise of dermatologists, from concept to counter (or store shelf); ensuring clinical efficacy, barrier health and results.

“CeraVe’s journey began and continues with dermatologists, ensuring superior skin health for all,” said Melanie Vidal, Global General Manager, CeraVe. “Through close collaboration, we’ve transformed their groundbreaking clinical insights into widely accessible, therapeutic solutions that truly enhance lives. As we celebrate two decades of CeraVe and our significant expansion into over 65 countries, we are more dedicated than ever to formulating trusted, barrier-focused products, developed in partnership with dermatologists, for every individual. This momentous occasion not only honors our past achievements but also ignites our drive for another twenty years of pioneering global skin health and advancing the science of the skin barrier.”

Key to CeraVe’s success is the unique formulation that pairs three skin-identical ceramides with trademarked MVE technology – a unique delivery system that releases ingredients gradually, providing hydration that goes 10 layers deep and lasts all day. From the beloved intense hydration of the AM & PM Facial Moisturizing Lotion for dry skin or the barrier-friendly approach of the new Anti-Dandruff Hydrating Shampoo and Conditioner, each product is a direct result of clinical insight and consumer need. This dedication to tailored, dermatologist-developed solutions, consistently infused with ceramides and MVE technology, is why CeraVe has earned such profound trust and widespread recommendations from skin health professionals worldwide. Indeed, in the US and Canada, CeraVe proudly holds the #1 recommended position among key healthcare professionals, including dermatologists, pharmacists, and pediatricians2, underscoring its broad acceptance and efficacy across various medical specialties.

To celebrate this significant accomplishment, CeraVe hosted a global celebration: a birthday bash in New York City that brought together some of the world’s most-followed dermatologists, including Dr. Muneeb Shah, Dr. Mamina Turegano, Dr. Evan A. Rieder, Dr. Ted Lain, Professor Michael Cork, Dr. Esther Freedman, Dr. Dustin Portela, Dr. Wallace Nozile, Dr. Zoe Draelos, Dr. Nkem Ugonabo, Dr. Oyetewa Asempa, Dr. Leena Ramani, and Dr. Toral Vaidya, as well as some of TikTok’s biggest stars, including Charli D’Amelio (@charlidamelio), and Ari@Home (@ariatinsta). The event was held on World Skin Health Day, allowing CeraVe to further amplify its message of accessible, dermatologist-developed skincare and its dedication to improving skin health worldwide, particularly through its commitment to providing access to dermatological care in under-resourced communities through the brand’s Care For All social impact program.

As CeraVe looks to the future, the brand remains steadfast in its commitment to dermatologist-developed, science-backed skincare solutions; it continuously pushes the boundaries of innovation. Recent launches highlight groundbreaking new formats within their comprehensive portfolio. For instance, the transformative Blemish Clay-to-Foam Cleanser offers a 3-in-1 solution for blemish-prone skin; it visibly reduces pimples and post-acne marks in just three days. The gentle cleansing Balancing Air Foam Facial Cleanser, designed for combination skin, features Breakthrough Glycolysine™ Technology, providing 8-Hour Oil Control and 24-Hour Hydration. Additionally, CeraVe Blemish Barrier Patches are now available; these leverage advanced hydrocolloid technology with 3 essential ceramides and niacinamide, visibly flattening blemishes in 3 hours, absorbing excess oil, and helping prevent post-acne marks. These innovations collectively underscore CeraVe’s dedication to accessible and cutting-edge skincare for all. Beyond skincare, CeraVe marked a significant milestone in the past year by successfully entering the brand new hair care category with its Anti-Dandruff and Gentle Haircare lines. The CeraVe Anti-Dandruff Shampoo and Conditioner when used as a system eliminates up to 100% of visible flakes without disrupting the scalp barrier, while also alleviating symptoms of mild to moderate dandruff and leaving hair healthy and soft. This bold venture has notably been recognized as the most successful hair care launch according to Nielsen data3.

“As one of the first dermatologists involved in the development of CeraVe, I am proud to be part of a brand that has held true to their clinical roots,” said Dermatologist Dr. Zoe Draelos. “CeraVe remains committed to involving dermatologists in the development and testing process – that’s why it’s one of the most effective skincare brands.  It will be exciting to see the future brand innovations, as my fellow dermatologists continue to seek out accessible, beneficial skincare products for all.” 

Beyond its scientific rigor, CeraVe has consistently engaged its audience through its signature “medutainment” style – a unique blend of education and entertainment – with a series of noteworthy campaigns over the past two decades. From the iconic Michael CeraVe Super Bowl commercial that playfully embraced the brand’s name, to the destigmatizing of dandruff with the “Head of CeraVe” campaign, and most recently, its Sarah V. GOAT mascot, CeraVe has masterfully utilized these platforms to get its core messaging across and re-emphasize its status as a brand developed with dermatologists.

1Source: Survey conducted among the dermocosmetic market carried out by APLUSA and its other partners between January 2024 and May 2024, involving dermatologists in 29 countries

2Source: The #1 recommended positions are supported by the following:

  • US Dermatologists: CeraVe is the #1 recommended position among dermatologists in the US. Source: IQVIA, ProVoice Survey, rolling 12-month data as of January 2025.
  • US Pharmacists: CeraVe is the #1 Pharmacist Recommended Skincare Brand in US. Based on an independent national survey of pharmacists, June 2025.
  • US Pediatricians: CeraVe is the #1 Pediatrician Recommended Skincare Brand in US. Based on ProVoice National Pediatrician Survey, June 2024.
  • Canada Healthcare Professionals: CeraVe is the N°1 General Practitioners (or Doctor) recommended brand, N°1 Pediatricians recommended brand, N°1 Pharmacists recommended brand, and N°1 Healthcare Professionals recommended brand in Canada. Source: IQVIA, Provoice Survey Q2 2024 – Q1 2025.

3Source: Nielsen Data

About CeraVe: 
Founded in 2005 and developed with dermatologists, CeraVe is the first and only brand to offer a complete line of products containing essential ceramides and MVE technology to help restore the skin’s natural protective barrier. CeraVe has a full line of skincare products to follow the dermatologist-recommended steps of: cleanse, treat, moisturize and protect. The brand’s mission is to provide therapeutic skincare for all. For more information, visit the brand on Facebook (@ceraveusa), Instagram (@cerave), TikTok (@cerave), X (@cerave) or at www.cerave.com.

Contact: 

Mia Kain                                 

Daria Sprague

CeraVe                                               

Ogilvy

mia.kain@loreal.com             

daria.sprague@ogilvy.com

 

Dr. Ted Lain and Tom Allison
Dr. Ted Lain and Tom Allison

 

CeraVe 20th Birthday Panel
CeraVe 20th Birthday Panel

 

Dr. Dustin Portela
Dr. Dustin Portela

 

Dr. Ted Lain
Dr. Ted Lain

 

CeraVe 20th Birthday Attendees
CeraVe 20th Birthday Attendees